GLP-1 receptor agonist-based treatment

GLP-1 receptor agonist-based treatment decreases body weight in humans (16%–27% of initial body weight).

“they were treated with semaglutide and tirzepatide resulting in weight loss between 16%-27% of initial body weight.”

Human trialClass III obesity with a loss-of-function PCSK1 mutationfemalesn = 2

GLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports

Obesity facts·12 Oct 2026